Bayer leads new €20m consortium aiming to optimize drug design
This article was originally published in Scrip
Executive Summary
Bayer HealthCare and Leiden University of the Netherlands are set to co-ordinate a newly founded international consortium comprising 20 partners, with the aim of optimizing drug design to reduce the rate of failure in clinical trials. The consortium is backed by Europe's Innovative Medicines Initiative (IMI), which has given €20 million in funding.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.